Milestone Pharmaceuticals enrolls first Canadian patient in AFib trial

September 24, 2026 8:01 AM

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced that the Montreal Heart Institute has enrolled the first Canadian participant in its ReVeRA-301 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found